Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Between subjects variability in haemoglobin and dose are not associated with the erythropoiesis-stimulating agent used to treat anaemia in dialysis: a meta-analysis.

Pérez-Ruixo JJ, Cucala-Ramos M, García-Gonzalo E, Del Val Romero B, Valveny N.

Br J Clin Pharmacol. 2013 Jan;75(1):15-25. doi: 10.1111/j.1365-2125.2012.04383.x.

2.

Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patients.

Hahn D, Cody JD, Hodson EM.

Cochrane Database Syst Rev. 2014 May 28;(5):CD003895. doi: 10.1002/14651858.CD003895.pub3. Review.

PMID:
24872328
3.

Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo).

Locatelli F, Canaud B, Giacardy F, Martin-Malo A, Baker N, Wilson J.

Nephrol Dial Transplant. 2003 Feb;18(2):362-9.

PMID:
12543893
4.

Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: a combined analysis of eight multicenter trials.

Mann J, Kessler M, Villa G, Martinez-Castelao A, Feldt-Rasmussen B, Cruz J, Hörl WH, Mattin C, Praml C, Wilkie M.

Clin Nephrol. 2007 Mar;67(3):140-8.

PMID:
17390738
6.

2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.

Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, Kuriyama S, Komatsu Y, Suzuki M, Nakai S, Hattori M, Babazono T, Hiramatsu M, Yamamoto H, Bessho M, Akizawa T.

Ther Apher Dial. 2010 Jun;14(3):240-75. doi: 10.1111/j.1744-9987.2010.00836.x.

PMID:
20609178
7.

Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.

Brunkhorst R, Bommer J, Braun J, Haag-Weber M, Gill C, Wagner J, Wagener T; German Aranesp Study Group..

Nephrol Dial Transplant. 2004 May;19(5):1224-30. Epub 2004 Feb 19.

PMID:
14993489
8.
9.

Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis.

Kawahara K, Minakuchi J, Yokota N, Suekane H, Tsuchida K, Kawashima S.

Nephrology (Carlton). 2015 Dec;20 Suppl 4:29-32. doi: 10.1111/nep.12647.

PMID:
26456375
10.
11.

Preservation of anemia control and weekly ESA dosage after conversion from PEG-Epoetin beta to darbepoetin alfa in adult hemodialysis patients: the TRANSFORM study.

Donck J, Gonzalez-Tabares L, Chanliau J, Martin H, Stamatelou K, Manamley N, Farouk M, Addison J.

Adv Ther. 2014 Nov;31(11):1155-68. doi: 10.1007/s12325-014-0161-5. Epub 2014 Nov 1.

12.

Monthly administration of a continuous erythropoietin receptor activator provides efficient haemoglobin control in non-dialysis patients during routine clinical practice: results from the non-interventional, single-cohort, multicentre, SUPRA study.

Heidenreich S, Leistikow F, Zinn S, Baumann J, Atzeni A, Bajeski V, Dietzmann J, Dragoun GP; SUPRA Study Group..

Clin Drug Investig. 2012 Feb 1;32(2):99-110. doi: 10.2165/11594040-000000000-00000.

PMID:
22117178
13.

[Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].

Martínez Castelao A, Reyes A, Valdés F, Otero A, López de Novales E, Pallardó L, Tabernero JM, Hernández Jaras J, Lladós F.

Nefrologia. 2003;23(2):114-24. Spanish.

14.

Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients.

Jadoul M, Vanrenterghem Y, Foret M, Walker R, Gray SJ.

Nephrol Dial Transplant. 2004 Apr;19(4):898-903.

PMID:
15031347
15.

Chronic dialysis-associated anaemia in end-stage renal disease: analysis of management in two French centres.

Perrinet M, Décaudin B, Champs BB, Heran I, Urbina MA, Lemaitre V, Azar R, Odou P.

J Clin Pharm Ther. 2010 Aug;35(4):395-400. doi: 10.1111/j.1365-2710.2009.01106.x.

PMID:
20831542
16.

[Opatija study: observation of hemodialysis patients and titration of CERA dose just switched from another erythropoiesis stimulating agent].

Jelić I, Lovcić V, Kurtović I, Josipović M, Havranek Z, Kostić L, Racki S.

Acta Med Croatica. 2012 Jul;66(3):157-64. Croatian.

PMID:
23441529
17.

C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis.

Roger SD, Locatelli F, Woitas RP, Laville M, Tobe SW, Provenzano R, Golper TA, Ruangkanchanasetr P, Lee HY, Wu KD, Nowicki M, Ladanyi A, Martínez-Castelao A, Beyer U, Dougherty FC.

Nephrol Dial Transplant. 2011 Dec;26(12):3980-6. doi: 10.1093/ndt/gfr160. Epub 2011 Apr 19.

18.

Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia.

van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJ, Wasserman SM, Baker N, Rosser D, Cleland JG, Ponikowski P.

Eur Heart J. 2007 Sep;28(18):2208-16. Epub 2007 Aug 6.

PMID:
17681958
19.

Switch of ESA therapy from darbepoetin-alpha to epoetin-beta in hemodialysis patients: a single-center experience.

Biggar P, Ketteler M, Hennemann H, Dömling R.

Clin Nephrol. 2008 Mar;69(3):185-92.

PMID:
18397717
20.

Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009.

Regidor D, McClellan WM, Kewalramani R, Sharma A, Bradbury BD.

Nephrol Dial Transplant. 2011 May;26(5):1583-91. doi: 10.1093/ndt/gfq573. Epub 2010 Sep 22.

PMID:
20861195

Supplemental Content

Support Center